A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 7,800 shares of ORIC stock, worth $68,874. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,800
Holding current value
$68,874
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.52 - $11.9 $43,367 - $68,627
5,767 New
5,767 $59,000
Q3 2023

Nov 14, 2023

BUY
$6.05 - $9.28 $403,728 - $619,272
66,732 Added 85.25%
145,007 $877,000
Q2 2023

Aug 14, 2023

SELL
$4.95 - $8.4 $204,573 - $347,155
-41,328 Reduced 34.55%
78,275 $607,000
Q1 2023

May 15, 2023

BUY
$4.26 - $6.75 $174,532 - $276,547
40,970 Added 52.1%
119,603 $681,000
Q4 2022

Feb 14, 2023

BUY
$2.41 - $5.89 $159,532 - $389,894
66,196 Added 532.25%
78,633 $463,000
Q3 2022

Nov 14, 2022

SELL
$3.15 - $5.24 $592,042 - $984,858
-187,950 Reduced 93.79%
12,437 $40,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.07 $81,810 - $214,221
-30,300 Reduced 13.13%
200,387 $898,000
Q1 2022

May 16, 2022

BUY
$4.54 - $16.1 $977,507 - $3.47 Million
215,310 Added 1400.21%
230,687 $1.23 Million
Q3 2021

Nov 15, 2021

SELL
$15.9 - $25.22 $62,614 - $99,316
-3,938 Reduced 20.39%
15,377 $322,000
Q2 2021

Aug 16, 2021

BUY
$17.37 - $25.34 $335,501 - $489,442
19,315 New
19,315 $341,000
Q1 2021

May 17, 2021

SELL
$23.67 - $36.85 $957,096 - $1.49 Million
-40,435 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$20.32 - $39.8 $544,007 - $1.07 Million
-26,772 Reduced 39.84%
40,435 $1.37 Million
Q3 2020

Nov 16, 2020

BUY
$19.5 - $31.26 $1.18 Million - $1.89 Million
60,376 Added 883.85%
67,207 $1.68 Million
Q2 2020

Aug 14, 2020

BUY
$25.68 - $38.12 $175,420 - $260,397
6,831 New
6,831 $230,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $349M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.